MyFinsight
Home
Blog
About
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$16,064,242
Unit: Dollar
Positive Cash Flow Breakdown
Net proceeds from issuance of de...
Accounts payable
Loss on retirement of debt
Others
Negative Cash Flow Breakdown
Loan repayment
Interest expense
Loan principal payment
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total operating expenses
6,496,734
6,521,087
6,674,708
24,869,251
Interest income
125,405
186,814
224,659
992,582
Interest expense
3,379,246
1,014,783
1,112,870
4,225,737
Benefit from income taxes
0
0
0
-1,169,820
Net loss
-9,750,575
-7,349,056
-7,562,919
-9,009,411
Stock-based compensation expense
1,126,054
1,156,495
1,158,210
1,246,485
Issuance of shares in consulting agreements
0
0
95,000
0
Amortization of debt discount
265,549
448,837
474,408
-307,179
Loss on retirement of debt
-2,660,781
-
-354,166
-752,838
Depreciation expense
8,387
5,459
5,459
5,459
Finance lease depreciation expense
6,742
9,670
9,672
9,670
Prepaid expenses and other assets
223,558
-764,455
-4,709,906
-80,290
Accounts payable
2,743,615
75,904
-1,606,480
683,494
Accrued expenses
370,496
516,590
-1,340,007
622,306
Operating lease liabilities
-
-
0
-
Net cash used in operating activities
-2,792,509
-4,371,646
-3,702,585
-5,916,048
Purchase of equipment
-
-
0
0
Net cash used in investing activities
-
-
0
0
Proceeds from issuance of pre-funded warrants
0
0
1,038,094
-
Proceeds from exercise of pre-funded warrants
0
0
6
0
Proceeds from issuance of pre-funded warrants
-
-
-
0
Proceeds from exercise of stock options
-
-
0
0
Proceeds from issuance of warrants
1,054,908
0
3,165,040
0
Payments of finance lease obligations
7,483
13,198
15,806
15,451
Loan principal payment
1,000,000
1,500,000
1,500,000
1,000,000
Loan repayment
17,738,889
-
354,167
0
Net proceeds from issuance of debt
4,322,500
-
-1,073,089
4
Proceeds from issuance of common stock from the sales agreement, net
-
-
-
1,256,652
Proceeds from issuance of common stock from at-the-market program, net of issuance costs
97,231
833,371
4,274,312
-
Proceeds from issuance of common stock, net of issuance costs
0
0
2,714,890
0
Net cash (used)/provided by financing activities
-13,271,733
-679,827
4,215,902
241,205
Net increase in cash and cash equivalents
-16,064,242
-5,051,473
513,317
-5,674,843
Cash and cash equivalents at beginning of period
21,660,496
26,711,969
26,198,652
41,689,591
Cash and cash equivalents at the end of period
5,596,254
21,660,496
26,711,969
26,198,652
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase in cash
and cash...
-$16,064,242
(-63.65%↓ Y/Y)
Net proceeds from
issuance of debt
$4,322,500
(-77.53%↓ Y/Y)
Proceeds from issuance of
warrants
$1,054,908
(-50.95%↓ Y/Y)
Proceeds from issuance of
common stock from...
$97,231
Accounts payable
$2,743,615
(-2.45%↓ Y/Y)
Loss on retirement of
debt
-$2,660,781
Stock-based compensation
expense
$1,126,054
(-33.84%↓ Y/Y)
Accrued expenses
$370,496
(126.82%↑ Y/Y)
Amortization of debt discount
$265,549
(-80.85%↓ Y/Y)
Depreciation expense
$8,387
(-23.18%↓ Y/Y)
Finance lease
depreciation expense
$6,742
(-65.14%↓ Y/Y)
Net cash
(used)/provided by financing...
-$13,271,733
(-259.57%↓ Y/Y)
Net cash used in
operating activities
-$2,792,509
(84.60%↑ Y/Y)
Canceled cashflow
$5,474,639
Canceled cashflow
$7,181,624
Interest income
$125,405
Loan repayment
$17,738,889
(-4.86%↓ Y/Y)
Net loss
-$9,750,575
(45.60%↑ Y/Y)
Loan principal
payment
$1,000,000
(-76.00%↓ Y/Y)
Payments of finance lease
obligations
$7,483
(-74.94%↓ Y/Y)
Canceled cashflow
$125,405
Prepaid expenses and
other assets
$223,558
(-95.50%↓ Y/Y)
Total operating
expenses
$6,496,734
Interest expense
$3,379,246
Buy us a coffee